Reading time ( words)
ITL Group, a Gooch & Housego company, has secured a major R&D contract with a global Chinese diagnostics company specializing in in-vitro diagnostics (IVD).
The company intends to fully utilize ITL’s experienced R&D team for the complete development of a microfluidic cartridge and molecular point-of-care diagnostic system for the detection of respiratory infections in children.
All R&D for the project will be carried out at ITL’s UK headquarters based in Ashford, Kent. The team will carry out feasibility studies, extensive market research and concept design in order to identify the best route forward.
One of the key factors in securing the contract was ITL’s ISO 13485 accredited manufacturing facility in Shanghai. With long-term plans to manufacture the product in China, it was hugely beneficial to find a contract partner with a full understanding of the Chinese language, regulatory landscape, business, and cultural environment, and the importance of building relationships within the country.
“This is a really exciting time for us. We’ve seen phenomenal growth over the last few years, with an outstanding 20% growth in first half of 2019. This contract is one of many that we have secured this year and it’s truly a credit to our employees and our 42 years in the MedTech industry,” said Tom Cole, managing director of ITL.
